Sarah Cannon Research Institute Names Director and Executive Director of Its Drug Development Program

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Sarah Cannon Research Institute (SCRI) has promoted Jeffrey R. Infante, M.D., to Director, Drug Development for the Nashville based program where he previously served as associate director. Howard A. “Skip” Burris III, M.D., chief medical officer for the organization, will assume the role of executive director for the overall drug development initiative.

Dr. Infante received his undergraduate and medical degrees from the University of Florida. His residency was completed at Parkland Memorial Hospital, University of Texas Southwestern Medical Center and his fellowship in medical oncology was completed at Johns Hopkins University School of Medicine. He also earned a master of health science degree in epidemiology at Johns Hopkins University’s Bloomberg School of Public Health.

“Dr. Infante has quickly emerged as a respected leader in the study of investigational agents,” said Dr. Burris. “He has authored numerous abstracts that have received international recognition in the oncology community, and his expansive knowledge of early drug development will serve this directorship well.”

Dr. Burris will provide executive oversight of SCRI’s four drug development programs in Nashville and London, along with Oklahoma University and Florida Cancer Specialists in his expanded role. He received his undergraduate degree from the U.S. Military Academy, West Point and medical degree from the University of South Alabama. He performed his residency and fellowship in hematology and oncology at Brooke Army Medical Center in San Antonio.

“Dr. Burris has over two decades of Phase I clinical trial experience that has provided the foundation of our very successful drug development program, which he founded in 1997,” SCRI Chief Executive Officer Dee Anna Smith said. “His deep knowledge of science and drug development strategy is a tremendous asset to our organization and allows us to achieve our mission of advancing therapies for patients.”

The SCRI drug development program enrolled over 600 patients on clinical trials in 2010 and has conducted 88 first-in-man trials to date. The Nashville unit includes a 20,000 square foot outpatient treatment clinic that has full pharmacokinetic and pharmacodynamic capabilities.

SCRI is a global strategic research organization focusing on advancing therapies and accelerating drug development. It is one of the largest clinical research programs, conducting community-based clinical trials in oncology, cardiology, gastroenterology and other therapeutic areas through affiliations with a network of more than 700 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites. For more information, please visit

Find us on Facebook and Twitter:!/sarahCannonPR


Sarah Cannon Research Institute
Anna Walker, 615-329-7216
[email protected]

KEYWORDS:   United Kingdom  United States  Europe  North America  Tennessee

INDUSTRY KEYWORDS:   Health  Hospitals  Oncology  Pharmaceutical  Research  Science